{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T21:48:47Z","timestamp":1781560127638,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"am","delay-in-days":329,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"NCATS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","atherosclerosis-journal.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.atherosclerosis.2024.117541","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T02:57:40Z","timestamp":1713236260000},"page":"117541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["An evaluation of the cost-effectiveness of population genetic screening for familial hypercholesterolemia in US patients"],"prefix":"10.1016","volume":"393","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8394-3917","authenticated-orcid":false,"given":"Lauren E.","family":"Hendy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa P.","family":"Spees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delesha M.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen C.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan C.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.117541_bib1","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel","volume":"72","author":"Sturm","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"21","key":"10.1016\/j.atherosclerosis.2024.117541_bib2","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1161\/CIRCULATIONAHA.117.032321","article-title":"Prevalence and Predictors of cholesterol screening, Awareness, and statin treatment among US adults with familial hypercholesterolemia or other Forms of severe Dyslipidemia (1999-2014)","volume":"137","author":"Bucholz","year":"2018","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.atherosclerosis.2024.117541_bib3","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013225","article-title":"Diagnosis and treatment of Heterozygous familial hypercholesterolemia","volume":"8","author":"McGowan","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2024.117541_bib4","unstructured":"\u201cTier 1 Genomics Applications and their Importance to Public Health | CDC.\u201d Accessed: March. 2, 2022. [Online]. Available: https:\/\/www.cdc.gov\/genomics\/implementation\/toolkit\/tier1.htm."},{"issue":"45","key":"10.1016\/j.atherosclerosis.2024.117541_bib5","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"issue":"22","key":"10.1016\/j.atherosclerosis.2024.117541_bib6","first-page":"S1933","article-title":"Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States","author":"Spencer","year":"2022","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.117541_bib7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/M22-0846","article-title":"Population genomic screening for three common hereditary conditions : a cost-effectiveness analysis","volume":"176","author":"Guzauskas","year":"2023","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.117541_bib8","first-page":"228","article-title":"A practical, robust implementation and sustainability model (PRISM) for integrating research findings into practice","volume":"34","author":"Feldstein","year":"2008","journal-title":"Joint Comm. J. Qual. Patient Saf."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.117541_bib9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12687-013-0140-6","article-title":"Genetic susceptibility testing for chronic disease and intention for behavior change in healthy young adults","volume":"4","author":"Vassy","year":"2013","journal-title":"J Community Genet"},{"key":"10.1016\/j.atherosclerosis.2024.117541_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.867226","article-title":"The impact of proband Indication for genetic testing on the uptake of cascade testing among relatives","volume":"13","author":"Schmidlen","year":"2022","journal-title":"Front. Genet."},{"issue":"24","key":"10.1016\/j.atherosclerosis.2024.117541_bib11","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1161\/CIRCULATIONAHA.108.816694","article-title":"Predicting the 30-year risk of cardiovascular disease: the framingham heart study","volume":"119","author":"Pencina","year":"2009","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.117541_bib12","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3390\/jcm8071080","article-title":"Incidence of cardiovascular disease in patients with familial hypercholesterolemia Phenotype: analysis of 5 Years Follow-Up of Real-World data from more than 1.5 Million patients","volume":"8","author":"Masana","year":"2019","journal-title":"J. Clin. Med."},{"issue":"19","key":"10.1016\/j.atherosclerosis.2024.117541_bib13","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.2015.15629","article-title":"Statins for prevention of cardiovascular disease in adults: Evidence report and systematic review for the US preventive services Task Force","volume":"316","author":"Chou","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.117541_bib14","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2016.04.054","article-title":"Statins in familial hypercholesterolemia: Consequences for coronary Artery disease and All-cause Mortality","volume":"68","author":"Besseling","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.117541_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010376","article-title":"Adherence to statin therapy among US adults between 2007 and 2014","volume":"8","author":"Colantonio","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2024.117541_bib16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/CEOR.S76972","article-title":"Medical costs associated with cardiovascular events among high-risk patients with hyperlipidemia","volume":"7","author":"Bonafede","year":"2015","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.atherosclerosis.2024.117541_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12872-016-0190-x","article-title":"Clinical and economic burden associated with cardiovascular events among patients with hyperlipidemia: a retrospective cohort study","volume":"16","author":"Fox","year":"2016","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.atherosclerosis.2024.117541_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12913-015-0772-9","article-title":"Acute and chronic impact of cardiovascular events on health state utilities","volume":"15","author":"Matza","year":"2015","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.atherosclerosis.2024.117541_bib19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12955-020-01407-y","article-title":"Utility value estimates in cardiovascular disease and the effect of changing elicitation methods: a systematic literature review","volume":"18","author":"Betts","year":"2020","journal-title":"Health Qual. Life Outcome"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.117541_bib20","first-page":"155","article-title":"Quantifying the utility of taking pills for cardiovascular prevention","volume":"8","author":"Hutchins","year":"2015","journal-title":"Circulation: Cardiovascular Quality and Outcomes"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2024.117541_bib21","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s11136-019-02163-3","article-title":"Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences","volume":"28","author":"Matza","year":"2019","journal-title":"Qual. Life Res."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.117541_bib22","article-title":"Estimating long-term health utility scores and Expenditures for cardiovascular disease from the medical Expenditure panel survey","volume":"14","author":"Morey","year":"2021","journal-title":"Circulation: Cardiovascular Quality and Outcomes"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2024.117541_bib23","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2165\/11314000-000000000-00000","article-title":"Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster","volume":"27","author":"Lieu","year":"2009","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.117541_bib24","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000324703","article-title":"Interest in genetic testing for modest changes in breast cancer risk: implications for SNP testing","volume":"14","author":"Graves","year":"2011","journal-title":"Public Health Genomics"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.117541_bib25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10754-010-9082-2","article-title":"Assessing willingness to pay for cancer prevention","volume":"10","author":"Milligan","year":"2010","journal-title":"Int. J. Health Care Finance Econ."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2024.117541_bib26","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40273-020-00942-2","article-title":"Perspective and costing in cost-effectiveness analysis, 1974\u20132018","volume":"38","author":"Kim","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.atherosclerosis.2024.117541_bib27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.atherosclerosis.2018.01.036","article-title":"The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland","volume":"270","author":"Pelczarska","year":"2018","journal-title":"Atherosclerosis"},{"issue":"7349","key":"10.1016\/j.atherosclerosis.2024.117541_bib28","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1136\/bmj.324.7349.1303","article-title":"Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia","volume":"324","author":"Marks","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2024.117541_bib29","first-page":"ehab770","article-title":"Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis","author":"Marquina","year":"2021","journal-title":"Eur. Heart J."},{"issue":"6319","key":"10.1016\/j.atherosclerosis.2024.117541_bib30","doi-asserted-by":"crossref","first-page":"aaf7000","DOI":"10.1126\/science.aaf7000","article-title":"Genetic identification of familial hypercholesterolemia within a single U.S. health care system","volume":"354","author":"Abul-Husn","year":"2016","journal-title":"Science"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024001011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024001011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T04:18:22Z","timestamp":1714969102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915024001011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":30,"alternative-id":["S0021915024001011"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117541","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An evaluation of the cost-effectiveness of population genetic screening for familial hypercholesterolemia in US patients","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117541","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117541"}}